 price
hip hop still cool
syk move part think manag
good job call explain varianc key debat
print whether headlin organ beat whisper expect
given easier comp extra sell day posit side
ortho came well knee hip crush
mako placement solid util seem tad soft qoq
mako procedur flat hard make call given
season soft commentari around mako adopt give
bull cheer continu out-performance ortho instrument
soft thought manag explan sale forc
split earli year impact along
commentari around capital-expenditure order book remain solid enough
allay concern final spine continu remain soft
thought datapoint manufactur capac transit
inhous limit factor provid comfort around
pro forma spine return growth margin execut came
one-tim integr cost impact
normal think call provid enough clariti
continu remain premium growth compani
level stock trade close ep caus us
remain sidelin
hip knee crush
leverag begin show w/ omx
legaci spine soft w/ lower guid lsd msd
came light integr cost
pleas see analyst certif import disclosur page report evercor isi affili seek busi
compani cover research report investor awar firm may conflict interest could affect object
report investor consid report singl factor make invest decis
rais ep vs prior
indic high end organ growth
fx impact rais
robot global us nearli robot global us instal base
sold japan launch
mako mean procedur total procedur
hip
dd growth em eu japan canada
medsurg particularli strong ou organ sale growth
transform translat omx net currenc dilut
price less unfavor expect
slower organ due spine soft
endoscopi us organ led gener surgeri video product platform
us led acut care bed
spine neurotech soft msd growth spine off-set soft us neurotech
us organ led dd growth neurovascular
ou driven neurotech
spine saw hw us price eros
spine guidanc lower lsd vs msd prior guid
ortho us organ growth ou
strong demand mako tka shoulder implant
emerg market growth call major contributor ou growth
trauma extrem org growth us
alpha tibia nail system strong
gm due price mix
om expand driven leverag save off-set dilut
tax benefit stock-bas comp
number sell day
bs cash held ou
total debt
ytd cash op bn
repurchas common stock
expect medic devic tax suspend
valuat methodolog base mix discount cash flow analysi rel valuat multipl
risk valuat includ regulatori risk overal market risk well unforeseen event relat individu cover
compani broader sector includ new competit product technolog
articl articl
time dissemin octob
analyst jon bristow vijay kumar primarili respons prepar research report attest follow view
opinion render research report reflect person view subject compani issuer part
research analyst compens directli relat specif recommend view research report
